Register for the 2023 SOSV Climate Tech Summit on Sept. 26-27.

Cayuga Biotech

Providing unmatched treatments that address all forms of bleeding


Kyle Ploense


Nathan Ogden


Damien Kudela


Company details

Cayuga Biotech is a startup company developing novel hemostatic drugs and devices to treat uncontrollable bleeding episodes. Cayuga Biotech has created CAY001, a systemic drug designed to target bleeding in patients on anti-platelet drugs to reduce blood loss and save lives. CAY001’s mechanism of action potentially gives it a better safety profile than current drugs on the market, a key competitive advantage.

Get In Touch with Cayuga Biotech

Please tell us a little bit about yourself and why you'd like to get connected. Cayuga Biotech + SOSV will follow up with you via email.

* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.